A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer.
Stefan Buchholz
Research Funding - Clinical search
Joerg Engel
Employment or Leadership Position - Aeterna Zentaris (I)
Stock Ownership - Aeterna Zentaris (I)
Other Remuneration - travel fundings
Andrew V. Schally
Consultant or Advisory Role - Patents
Research Funding - Aeterna Zentaris
Stephan Seitz
No relevant relationships to disclose
Olaf Ortmann
No relevant relationships to disclose
Guenter Emons
Research Funding - Research Funds
Reshma L. Mahtani
No relevant relationships to disclose
Stefan Gluck
No relevant relationships to disclose
Charles L. Vogel
No relevant relationships to disclose
Alberto J. Montero
No relevant relationships to disclose